| 1 |
Stojanovich L, Stojanovich R, Kostich V, et al. Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study) [J]. Lupus, 2003,12(1):3-7.
|
| 2 |
Goswami RP, Sircar G, Sit H, et al. Cyclophosphamide versus mycophenolate versus rituximab in lupus nephritis remission induction: a historical head-to-head comparative study [J]. J Clin Rheumatol, 2019, 25(1): 28-35.
|
| 3 |
Bosch X, Guilabert A, Pallarés L, et a1. Infections in systemic lupus erythematosus:a prospective and controlled study of 110 patients [J]. Lupus, 2006, 15(9): 584-589．
|
| 4 |
Al-Rayes H, Al-Swailem R, Arfin M, et al. Systemic lupus erythematosus and infections: a retrospective study in Saudis [J]. Lupus, 2007, 16(9): 755-763.
|
| 5 |
中华医学会风湿病学分会. 系统性红斑狼疮诊断及治疗指南[J]. 中华风湿病学杂志, 2010, 14(5): 342-346.
|
| 6 |
Miyara M, Ito Y, Sakaguchi S. TREG-cell therapies for autoimmune rheumatic diseases [J]. Nat Rev Rheumatol, 2014, 10(9): 543-551.
|
| 7 |
Shevach EM. Mechanisms of foxp3＋ T regulatory cell-mediated suppression [J]. Immunity, 2009, 30(5): 636-645.
|
| 8 |
Sakaguchi S, Wing K, Onishi Y, et al. Regulatory T cells: how do they suppress immune responses? [J]. Int Immunol, 2009, 21(10): 1105-1111.
|
| 9 |
McNally A, Hill GR, Sparwasser T, et al. CD4＋CD25＋ regulatory T cells control CD8＋ T-cell effector differentiation by modulating IL-2 homeostasis [J]. Proc Natl Acad Sci USA, 2011, 108(18): 7529-7534.
|
| 10 |
Rubtsov YP, Rasmussen JP, Chi EY, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces [J]. Immunity, 2008, 28(4): 546-558.
|
| 11 |
Li MO, Wan YY, Flavell RA. T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1-and Th17-cell differentiation [J]. Immunity, 2007, 26(5): 579-591.
|
| 12 |
Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3＋ regulatory T cell function [J]. Science, 2008, 322(5899): 271-275.
|
| 13 |
Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation [J]. Nat Rev Immunol, 2007, 7(10): 817-823.
|
| 14 |
Setoguchi R, Hori S, Takahashi T, et al. Homeostatic maintenance of natural Foxp3＋ CD25＋ CD4＋ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization [J]. J Exp Med, 2005, 201(5): 723-735.
|
| 15 |
Fontenot JD, Rasmussen JP, Gavin MA, et al. A function for interleukin 2 in Foxp3-expressing regulatory T cells [J]. Nat Immunol, 2005, 6(11): 1142-1151.
|
| 16 |
Yang J, Yang X, Zou H, et al. Recovery of the immune balance between Th17 and regulatory T cells as a treatment for systemic lupus erythematosus [J]. Rheumatology (Oxford, England), 2011,50(8): 1366-1372.
|
| 17 |
Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease[J]. N Engl J Med, 2011, 365(22): 2055-2066.
|
| 18 |
Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis [J]. N Engl J Med, 2011, 365(22): 2067-2077.
|
| 19 |
Long SA, Rieck M, Sanda S, et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function [J]. Diabetes, 2012, 61(9): 2340-2348.
|
| 20 |
He J, Zhang X, Wei Y, et al. Low-dose interleukin-2 treatment selectively modulates CD4 (＋) T cell subsets in patients with systemic lupus erythematosus [J]. Nat Med, 2016, 22(9): 991-993.
|
| 21 |
Humrich JY, von Spee-Mayer C, Siegert E, et al. Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE [J]. Ann Rheum Dis, 2015, 74(4): 791-792.
|
| 22 |
Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy [J]. Immunity, 2013, 38(1): 13-25.
|
| 23 |
Bachmann MF, Oxenius A. Interleukin 2: from immunostimulation to immunoregulation and back again [J]. EMBO Rep, 2007, 8(12): 1142-1148.
|
| 24 |
Waldmann TA, Dubois S, Tagaya Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy [J]. Immunity, 2001, 14(2): 105-110.
|
| 25 |
Armant M, Delespesse G, Sarfati M. IL-2 and IL-7 but not IL-12 protect natural killer cells from death by apoptosis and up-regulate bcl-2 expression [J]. Immunology, 1995, 85(2): 331-337.
|